1 Correction to: Drugs (2021) https://doi.org/10.1007/s40265-021-01583-1

Section 2.3.1, right hand column, second paragraph, second sentence, which currently reads:


“… for tralokinumab 300 mg every 2 weeks and tralokinumab 300 mg every 2 weeks, respectively.”


Should read:


“… for tralokinumab 300 mg every 2 weeks and tralokinumab 300 mg every 4 weeks, respectively.”


Section 2.3.2.1, second paragraph, third sentence, which currently reads:


“Over the 16 week treatment period, patients receiving tralokinumab 300 mg every 2 weeks used 50% less of the supplied TCS compared with patients receiving placebo”


Should read:


“At weeks 15–16, patients receiving tralokinumab 300 mg every 2 weeks used 50% less of the supplied TCS compared with patients receiving placebo”


The original article has been corrected.